<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20020423143426Z</creation_date><modification_date>D:20060321211719+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-99-100_h_dec_5.pdf</pdf_file></head><body><section><header>en</header><p>commission of the european communitiesbrussels, 19/04/2002c(2002) 1571
 not for publication</p></section><section><header>commission decisionof 19/04/2002
 amending decision c(1999) 939 on the marketing authorization for
 the medicinal product for human use
 &quot;cetrotide - cetrorelix (as acetate)&quot;
 (text with eea relevance)</header><p>only the english text is authentic.</p></section><section><header>commission decisionof 19/04/2002
 amending decision c(1999) 939 on the marketing authorization for
 the medicinal product for human use
 &quot;cetrotide - cetrorelix (as acetate)&quot;
 (text with eea relevance)</header><p>the commission of the european communities,having regard to the treaty establishing the european community,
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down
 community procedures for the authorization and supervision of medicinal products for
 human and veterinary use and establishing a european agency for the evaluation of
 medicinal products
 1, as amended by commission regulation (ec) no 649/982,having regard to commission regulation (ec) no 542/95 of 10 march 1995 concerning
 the examination of variations to the terms of a marketing authorisation falling within the
 scope of council regulation (eec) no 2309/93
 3, as amended by commissionregulation (ec) no 1069/98
 4, and in particular article 5(2) thereof,having regard to the opinion of the european agency for the evaluation of medicinal
 products,
 whereas:
 (1)</p><p>the medicinal product &quot;cetrotide - cetrorelix (as acetate)&quot; entered in the
 community register of medicinal products under nos eu/1/99/100/001-003
 authorised by commission decision c(1999) 939 of 13 april 1999, as amended,
 complies with the requirements set out in regulation (eec) no 2309/93.
 (2)</p><p>serono europe ltd. submitted an application on 19 february 2002 pursuant to
 article 4(1) set out in regulation (ec) no 542/95.
 (3)</p><p>the european agency for the evaluation of medicinal products delivered a
 favourable opinion formulated on 15 march 2002 by the committee for
 proprietary medicinal products,
 (4)</p><p>decision c(1999) 939 should therefore be amended accordingly.</p><p> 
 1 oj no l 214, 24. 8. 1993, p. 1.2 oj l 88, 24.3.1998, p. 7.3 oj no l 55, 11.3.1995, p. 154 oj l 153, 27.5.1998, p. 11(5) in accordance with article 5(2) of regulation (ec) no 542/95, this decision shall
 take effect retroactively on the 31st day following receipt by the european
 agency for the evaluation of medicinal products of the application relating to it.
 has adopted this decision:
 article 1decision c(1999) 939 is amended as follows:1. annex ii is replaced by annex i to this decision;
 2. annex iii b is replaced by annex ii to this decision.
 article 2this decision shall apply from 21 march 2002.article 3this decision is addressed to serono europe ltd., 56, marsh wall, london e14 9tp,united kingdom.
 done at brussels, 19/04/2002
 for the commissionerkki liikanen
 member of the commission</p></section></body></xml>